1. 4.8% of breast cancer patients had BRCA1/BRCA2 variants.
2. Median age at diagnosis was 54 years.
3. Germline testing used blood, buccal, or saliva samples.
4. Variants were classified by American College of Medical Genetics and Genomics.
5. Prevalence varied among different racial groups.
6. Universal genetic testing is recommended for minoritized populations.
7. The study faced limitations like potential selection bias.

Source: JAMA Network Open